Randomised prostate cancer screening trial: 20 year follow-up

  title={Randomised prostate cancer screening trial: 20 year follow-up},
  author={Gabriel Sandblom and Eberhard Varenhorst and Johan Rosell and Owe L{\"o}fman and Per G. Carlsson},
  journal={The BMJ},
Objective To assess whether screening for prostate cancer reduces prostate cancer specific mortality. Design Population based randomised controlled trial. Setting Department of Urology, Norrköping, and the South-East Region Prostate Cancer Register. Participants All men aged 50-69 in the city of Norrköping, Sweden, identified in 1987 in the National Population Register (n=9026). Intervention From the study population, 1494 men were randomly allocated to be screened by including every sixth man… 
Prostate Cancer Screening: Outcomes and Risk Prediction
The four papers included in this thesis present the outcomes of PSA-based screening and also describe aspects of the risk of PC at initial screening, during the 22-year follow-up of the programme, and after termination of screening.
Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
The CAP trial successfully met its recruitment targets and will make an important contribution to international understanding of PSA-based prostate cancer screening, with little evidence of differences between trial arms in measured baseline characteristics of the consenting GP practices.
Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
Prostate-specific antigen-based screening results in small or no reduction in prostate cancer-specific mortality and is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary.
Risk stratification in prostate cancer screening
The PSA test needs to be combined with other predictive factors or be used in a more thoughtful way to identify men at risk of symptomatic or life-threatening cancer, without overdiagnosing indolent disease.
Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes.
Prostate Cancer Screening
There is no justification for the introduction of population-based organized screening for prostate cancer at any age; while in view of the potential harms associated with screening, physicians should generally recommend against PSA testing for asymptomatic men.
Screening for prostate cancer: Can randomized studies optimize the trade-off between over - and under-diagnosis?
Screening for prostate cancer may reduce prostate cancer mortality, but to the cost of over-detection and over-treatment.
Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening
  • Kazuto Ito, Ryo Oki, I. Kurosawa
  • Medicine
    International journal of urology : official journal of the Japanese Urological Association
  • 2019
Countermeasures against prostate cancer could be very important not only in Western countries, but also in developed Asian countries because differences in the incidence and mortality rate of prostate cancer between the USA and Japan have been decreasing over time, and were only twofold in 2017.
Population screening for prostate cancer: An overview of available studies and meta‐analysis
Excluding the main shortcomings in screening studies (short follow up, high prostate‐specific antigen contamination in non‐screening group and low participation in screening group), screening is able to reduce prostate cancer mortality.
Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review
The quality of evidence is downgraded to moderate due to the retrospective identification of subgroups and limited data on control group screening, and the benefit of screening for prostate cancer compares favorably with screening for other cancers.


Screening and prostate-cancer mortality in a randomized European study.
PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
Mortality results from a randomized prostate-cancer screening trial.
After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.
Non‐systematic screening for prostate cancer in SwedenSurvey from the National Prostate Cancer Registry
Investigating the cause of initiating a work‐up leading to a diagnosis of prostate cancer, with emphasis on T1c tumours found prostate cancer is still most commonly diagnosed during the work-up of symptomatic patients.
Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population.
Screening for carcinoma of the prostate by digital rectal examination can be organised with a high population acceptance, and at a reasonable cost, and the impact of screening on mortality in prostatic cancer remains uncertain.
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
Introduction of PSA screening will increase total healthcare costs for prostate cancer substantially, of which the actual screening costs will be a small part.
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.
Radical prostatectomy reduces prostate cancer mortality and risk of metastases with little or no further increase in benefit 10 or more years after surgery.
Validity of a Population-Based Cancer Register in Sweden An Assessment of Data Reproducibility in the South-East Region Prostate Cancer Register
The population-based setting and high coverage guarantees the external validity of the register, and the internal validity is ensured by the high reproducibility shown in the present study.